N/A N=104 Repetitive Transcranial Magnetic Stimulation Equipment Testing and Pilot Study
Healthy Volunteer
Primary: Behavioral Outcome Measure
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=132 A Study to Evaluate of Cosmetic Benefit of a Moisturising Cream in People With Blemish Prone Skin
Skin Care
Primary: Change From Baseline in Corneometer Values at 8 Hours on Day 1 — 6.14; 2.63; 3.60 Arbitrary Corneometer unit — p=0.0128
N/A N=1,305 Patients' Assessment of Satisfaction for Stroke Prevention in Atrial Fibrillation
Atrial Fibrillation
Primary: Mean Perception of Anticoagulant Treatment Questionnaire 2 (PACT-Q2) Scores, for Patients in Cohort A, at Second and Last Assessment Compared to Baseline Assessment…
Phase 1 N=47 A Study to Characterize Diclofenac's Plasma and Knee Exposure After Application of Diclofenac Gel to the Knee of Subjects With Osteoarthritis That Have a Scheduled Arthroplasty
Pain
Primary: Diclofenac Concentration in Treated Knee Synovial Tissue After 7 Days Topical Application of Study Treatment to the Knee (12 Hours After Last Administration of Study…
Phase 2 N=46 Rifaximin for Chronic Immune Activation in People With HIV
HIV
Primary: Changes in Soluble Cluster of Differentiation 14 (sCD14) Levels Between the Placebo and Rifaximin Phases of the Study — 0.0067; 0.0035 mcg/mL — p=0.51
Phase 4 N=24 On-Eye Optical Quality of Lotrafilcon B Lenses Over 12 Hours
Hyperopia · Myopia
Primary: Higher Order Aberrations — 0.001646; 0.002629 microns
N/A N=230 CorMatrix ECM for Carotid Repair Following Endarterectomy Registry
Carotid Stenosis
Primary: Carotid Procedure and Device Related Adverse Events to Determine Device Performance — 53; 10; 1; 2 Device related adverse events
Phase 2 N=30 Pilot Study to Determine Effects of the Btk Inhibitor PCI-32765 on Leukemia Cell Kinetics and Trafficking, Using Heavy Water Labeling in Subjects With CLL and SLL
Leukemia
Primary: Change in Leukemia Cell Death — 0.18; 1.5 percentage of cell death
Phase 2 N=156 A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges
ALK-positive Non-small Cell Lung Cancer
Primary: Overall Response Rate (ORR) Per Investigator Assessment — 35.7; 30.0; 50.0; 59.1 Percentage of participants
Phase 3 N=2,436 A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled Asthma
Asthma
Primary: Mean Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 24 — 0.024; 0.120; 0.134; 0.076 Liters — p=<0.001
Phase 3 N=225 Efficacy Study Of Tofacitinib In Pediatric JIA Population
Juvenile Idiopathic Arthritis
Primary: Double Blind Phase: Percentage of Participants With Disease Flare According to Pediatric Rheumatology Collaborative Study Group/Pediatric Rheumatology International…
Phase 3 N=636 Safety and Efficacy of Reduced Versus Standard Dose Efavirenz (EFV) Plus Two Nucleotides in Antiretroviral-naïve Adults.
HIV Infections
Primary: Percentage of Participants With Plasma HIV-1 RNA <200 Copies/mL 48 Weeks After Randomisation — 92.2; 94.1 percentage of participants — p=0.05
N/A N=51 Individualized Dosing Schedule of Inhaled Bronchodilator for Endotracheally Intubated COPD Patients
Chronic Obstructive Pulmonary Disease
Primary: ∆Raw (the Difference Between Measured and Target Airway Resistance) — 9; 44 percentage of relative Raw deviation
Phase 3 N=703 Efficacy and Safety of Vonoprazan Compared to Lansoprazole in the Maintenance Treatment of Erosive Esophagitis
Erosive Esophagitis
Primary: Percentage of Participants With Recurrence of Erosive Esophagitis as Confirmed on Endoscopy After the 24-week Maintenance Phase — 13.3; 12.3; 25.5 percentage of…
Phase 1 N=30 This Study in Healthy People Tests Whether Taking a Low Strength of Empagliflozin, Linagliptin, and Metformin Together in 1 Pill is the Same as Taking Them in Separate Pills
Healthy
Primary: Area Under the Concentration-time Curve of the Empagliflozin in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) — 2134.53; 2125.57…